First Nordic Launches Phase 1 Diamond Drill Program at High-Priority Nippas Target
Phase 1 will consist of up to 26 diamond drill holes to test two of three identified structural corridors at Nippas. Drilling is being carried out by Finland-based Comadev Oy and is designed to build on promising results from recent base-of-till / top-of-bedrock ("BoT/ToB") drilling. The third corridor identified to date is in an area dominated by bogs and will be tested in the winter after freeze-up. Based on the success of this program, FNM plans to complete up to an additional 5,000 m of drilling at Nippas through 2025.
Taj Singh, CEO of FNM, comments:"The commencement of drilling at Nippas marks another important milestone for our team and reflects the systematic, data-driven approach we take across our portfolio. With promising BoT/ToB and geochemical indicators, Nippas has the potential to become a cornerstone discovery within the Storjuktan land package and the broader Gold Line belt. This program is designed to advance our understanding of the target and lay the groundwork needed to unlock its full potential."
Nippas Phase 1 Drill Program Details
Target 1: A 2.2 km-long Au-As-Cu-Zn-Mo surface till anomaly coincident with strongly elevated ToB results (up to 2.66 ppm Au). The anomaly is located along a geophysical trend interpreted as a sheared contact between two lithological units. Target 1 will be initially tested with up to 3,600 m of diamond drilling in 16 holes over 1.4 km strike of identified structural feature, as shown in Figure 1.
Target 2: A parallel 2.0 km Au-As-Cu-Zn-Mo anomalous surface till trend, coincident with elevated gold in bedrock and glacial till. This trend is interpreted to be the sheared boundary between metasediments and a large granite intrusion. Target 2 will be tested with up to 1,400 m of drilling in 10 holes over a 1.3 km strike of the identified structural feature, shown below in Figure 1.
This focused Phase 1 program is designed to confirm the presence of mineralized shear corridors, define their geometry and scale, and establish a robust geological model for further expansion.
As the Company awaits assay results from the Aida drill program, the Phase 1 program at Nippas ensures continued exploration activity and efficient use of the drill rig. Results from Nippas will also support broader geological understanding across the Storjuktan land package and inform future drill campaigns.
About the Nippas Target
The Nippas project is located within the Storjuktan project area along the Gold Line belt in northern Sweden. Pathfinder element signatures and magnetic geophysical trends are coincident with sheared contacts between metasediment, metavolcanic, and granitic lithologies. Three sub-parallel structural trends have been identified, with a combined strike length of over 5.2 km. These trends are situated within a regional flexure and coincide with several interpreted second-order splay structures along the margin of a large granite intrusion.
About the Storjuktan Project
The Storjuktan project is a large, early-stage project strategically positioned north of the Company's resource-stage Barsele project. It consists of seven contiguous licenses covering 30,000 ha located in the northern portion of the Gold Line belt. The Storjuktan project contains over 60 km of the regional Gold Line structural corridor. All mineralization discovered to date shows a spatial relationship to this structural corridor, occurring mainly on second- and third-order splay structures.
The Project contains over 60 km of the regionally significant "Gold Line" structure which can be traced for over 200 km in regional geophysics data. The Gold Line was first recognized in the late 1970s as a large arsenic-in-soil anomaly formed by a regional fault. All mineralization discovered to date shows a spatial relationship to this structural corridor, occurring either in the main shear corridor or on perpendicular structures within a few km of the main structures. The geology of the Storjuktan project consists of a sequence of inverted basin sediments and mafic volcanic rocks intruded by small syn-kinematic granitic intrusions within a broad, anastomosing high strain structural corridor. The rocks are regionally metamorphosed to amphibolite facies and gold mineralization is associated with intense biotite, and calc-silicate alteration assemblages and sulphide minerals pyrrhotite, arsenopyrite, and minor other sulphides. These lithological sequences are highly prospective for orogenic gold deposits.
ABOUT FIRST NORDIC METALS
First Nordic Metals Corp. is a Canadian-based gold exploration company, consolidating assets in Sweden and Finland, with a vision to create Europe's next gold camp. The Company's flagship asset is the Barsele gold project in northern Sweden, a joint venture project with senior gold producer Agnico Eagle Mines Limited. Immediately surrounding the Barsele project, FNM is 100%-owner of a district-scale license position comprised of two additional projects (Paubäcken, Storjuktan), which combined with Barsele, total approximately 100,000 hectares on the Gold Line greenstone belt. Additionally, in northern Finland, FNM is the 100%-owner of a district-scale position covering the entire underexplored Oijärvi greenstone belt, including the Kylmäkangas deposit, the largest known gold occurrence on this belt.
ON BEHALF OF THE BOARD OF DIRECTORS
Taj Singh, M.Eng, P.Eng, CPA
CEO & Director
Qualified Person
Benjamin Gelber, P. Geo., Exploration Head of FNM, is the Qualified Person as defined in NI 43-101, and takes responsibility for the technical disclosure contained within this news release.
For further information contact:
Marie Macdonald
Investor Relations
604-687-8566
[email protected]
Follow First Nordic Metals:
Twitter: @fnmetals
Youtube: @firstnordicmetalscorp
LinkedIn: @firstnordicmetals
Facebook: @FirstNordicMetals
Instagram: @firstnordicmetals
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward-Looking Statements
This news release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates and includes, statements with respect to (i) the NBU Acquisition, (ii) issuance of Shares thereunder, and (iii) receipt of TSXV approval of the NBU Acquisition. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this news release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that they will materialize or that the assumptions on which it is based are correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this news release are free from errors and readers of this news release should not place undue reliance on the forward-looking statements in this news release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of the date of this news release and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this news release, unless it is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
5 hours ago
- Toronto Star
Prime Drink Group Provides Bi-Weekly MCTO Status Report and Announces Closing of Private Placement
MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) ('Prime' or the 'Company') announces that further to its news release date July 30, 2025, the Company voluntarily applied for and the Company's principal regulator, the British Columbia Securities Commission (the 'BCSC') granted a management cease trade order (the 'MCTO') dated July 30, 2025, under National Policy 12-203 Management Cease Trade Orders ('NP 12-203') and provided the Company with an extension to file its annual financial statements for the period ended March 31, 2025, including the related management's discussion and analysis, and related certifications on or before July 29, 2025 (collectively the 'Annual Financial Filings'). The deadline has now been extended to on or before September 29, 2025. Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files its Annual Financial Filings on or before September 29, 2025, and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.
Globe and Mail
6 hours ago
- Globe and Mail
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK , Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000 . Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000 . The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025 , and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025 , in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Cision Canada
6 hours ago
- Cision Canada
Media advisory - Canada and Sweden advance their collaboration Français
STOCKHOLM, Sweden, Aug. 15, 2025 /CNW/ - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, will meet with Ebba Busch, Sweden's Deputy Prime Minister and Minister for Energy, Business and Industry in Stockholm to deepen Canada–Sweden relationship. They will be joined by the Honourable Stephen Fuhr, Secretary of State (Defence Procurement), and Pål Jonson, Sweden's Minister for Defence. Date: Monday, August 18, 2025 Time: 8:30 p.m. (Central European Time) Location: Stockholm, Sweden Note to media: This is a media spray only. Photo and video opportunity will be available at the top of the meeting. Members of the media are asked to contact Isabella Orozco-Madison at [email protected] to receive event location details and confirm their attendance. Stay connected SOURCE Innovation, Science and Economic Development Canada
